Abstract Fatigue is a highly prevalent but relatively ignored problem in IBD patients. It is one of the most burdensome symptoms to the patient with an important impact on the quality of life. Therefore, fatigue is a highly relevant patientreported outcome that should be included not only in disease activity measurement but also in the endpoints of clinical trials in IBD. However, most of the currently available scoring systems to quantify fatigue are not specifically designed for patients with IBD and none of them has undergone a complete validation process for IBD-related fatigue. Fatigue is more prevalent in patients with active disease and may improve or disappear when remission is reached. Far more complex is the persistence or onset of fatigue in quiescent IBD which presents in up to 40% of the patients. In this subgroup of patients, fatigue can be related to smoldering systemic inflammation, a poor sleep quality, anemia, nutritional deficiencies, or comorbidities. In most cases, however, no direct cause can be identified. The lack of knowledge on the mechanisms that drive fatigue in IBD hamper the development of specific drugs to treat the condition and only psychological support can be offered to the patient. Rodent models are indispensable to increase our understanding of the molecular pathways that lead to fatigue in chronic intestinal inflammation, and to develop novel therapies.
Introduction
Inflammatory bowel diseases (IBDs) are chronic inflammatory conditions of the gastrointestinal (GI) tract hallmarked by relapsing disease flare-ups and periods of remission. The major disease entities are Crohn's disease (which may involve the whole GI tract, the terminal ileum being the predilection site) and ulcerative colitis (which is limited to the colon) [1, 2] . IBDs are most commonly diagnosed between the age of 20 and 30 and can have a huge impact on the patient's personal, social, and professional life. Healthcare professionals tend to focus their attention to the gastrointestinal symptoms of the patient, and to the mucosal lesions that are seen during endoscopy. However, the real disease burden for the patient exceeds the digestive problems and many other aspects may contribute to a decreased quality of life (QoL) [3, 4] . Among these, fatigue is one of the most frequently patient-reported complaints. In a longitudinal IBD natural history outpatient registry from Pittsburgh, a high fatigue burden was found in 64.4% of Crohn's disease (CD) patients and 46.2% of ulcerative colitis (UC) patients with mixed disease activity [5] . In a French nationwide survey that provided data from 1185 IBD patients, almost half of the patients reported severe fatigue [3] . These results are consistent with an earlier systematic review in which the prevalence of fatigue in IBD was found to range from 40-86%, depending on the disease activity state and the used scale/cutoff for diagnosis of fatigue [6] . CD patients seem to be slightly more affected by fatigue than UC patients [6] [7] [8] [9] . The impact of fatigue on the patient's general well-being is nicely illustrated in a cross-sectional study from Ireland, in which 247 IBD patients were asked to report the symptoms they had experienced over the last week and to identify the most burdensome symptom [4] . A lack of energy was reported by 80.6 and 63.8% of the patients with active and inactive disease, respectively. Moreover, lack of energy was ranked as the most burdensome symptom, before bowel urgency and diarrhea [7] . Besides the impact on the QoL of the patient, fatigue also has significant economic consequences. Presenteeism and absenteeism at work, reduced overall activity, a reduced social life, and a reduced ability to travel all result in significant indirect costs that are frequently not taking into account in cost-impact analyses related to IBD [10] [11] [12] . In a prospective study performed at a high-volume tertiary IBD center in the USA, presenteeism was detected in 62.9% of IBD patients as compared to 27.3% of controls (P = 0.004) [13] .
Despite the very high prevalence of fatigue in IBD and its negative consequences, the problem is barely discussed during consultations at the outpatient clinic. The reason behind is that fatigue, especially during disease remission, is being considered as a difficult and frustrating symptom with very few opportunities to help the patient. Indeed, little is known on the pathogenesis of IBD-related fatigue and, as a consequence, no targeted intervention is possible. This important lack of information has been recognized by healthcare providers. In a recently completed large-scale modified Delphi survey with nurse and allied health professional members of the Nurses European Crohn's and Colitis Organisation, fatigue came out as one of the top ten priorities in IBD nursing research [14] . Likewise, in the James Lind Priority Setting Partnership, a UK initiative that brings together clinicians, patients, and other stakeholders to set research priorities for a variety of diseases, the association between IBD and fatigue and its management was put forward by both clinicians and patients as one of the ten research priorities in IBD [15] . In a recently published opinion paper by a group of senior IBD experts, a set of criteria to measure IBD severity was proposed based on not only (a) the measurable inflammatory burden and (b) the disease course but also (c) the impact of the disease on the patient, including fatigue [16] .
While awaiting the identification of more specific treatment targets, it is important to identify the patients suffering from this IBD-associated condition and to not ignore it but to set up a standardized strategy for optimal management of this debilitating symptom in order to improve the patient's QoL.
Search Process
We searched for relevant publications using PubMed, EMBASE, and the Cochrane Library from their inception until May 15, 2017. The search included the terms fatigue, tiredness, lack of energy, patient-reported outcomes, psychological, vitality and behavior combined with inflammatory bowel disease, IBD, Crohn's disease, and ulcerative colitis. We critically reviewed articles published in English and considered randomized controlled trials, cohort studies, cross-sectional studies, case series, and survey results. Finally, we searched the bibliographies of included articles and also considered abstracts presented at major meetings.
Diagnosis and Quantification of Fatigue
The diagnosis and quantification of pathological fatigue have been proven problematic. Fatigue is a common non-specific symptom that is detected in a wide range of chronic diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and also IBD. According to the definitions given in most clinical trials, fatigue can be defined as an overwhelming sense of tiredness, reduced energy levels, and feeling of exhaustion, that is not responsive to prolonged rest or sleep [17] .
Previous efforts from an independent working group aiming to define the multidimensional aspects of fatigue in cancer patients led to a consensus on seven characteristic features for fatigue as a trait: (1) it is subjective (self-reported), (2) abnormal (not proportional to prior activity and not relieved by rest), (3) the physical perceptions range from lassitude to exhaustion, which (4) have a negative impact on daily functioning (decreased capacity for work, decreased quality of life, poor sleep quality), (5) it is associated with unpleasant emotions (helplessness, anxiety, emotional numbness), (6) results in the decreased cognitive ability (attention, concentration), and (7) has an unpredictable temporal course [17] .
More than 250 self-report measurement systems exist for assessing fatigue, about 150 of which have been only used once [18, 19] . Unidimensional scales capture fatigue in a single score, thereby reducing the multilayered causes of the condition. However, these questionnaires are brief and therefore are easy to implement in large-scale studies, and may have good consistency and test-retest reliability [19] . In contrast, multidimensional scales do allow a multifaceted assessment. These scales determine the severity of fatigue and question how much the fatigue interferes with the quality of life, including assessment of its effect on social function, cognition, mood, and physical function. These data allow for comparing profiles across conditions or seeking mechanisms underlying fatigue. However, the validity of the variation in multidimensional scales varies greatly, and data on reliability are often missing.
Although it may seem good practice to ask patients to report on their current state of fatigue to avoid retrospective bias, the variable temporal course can be missed. Therefore, scales generally ask for a judgment over some predefined reporting period (e.g., over the past week) which varies across scales.
Up to date, a consensus definition or method for assessment of fatigue in IBD is lacking. Based on a literature review on fatigue in IBD from 2013, nine different scales were used [20] . The rationale for the specific choice was not provided, and most of the scales had never been tested in IBD. Since, more data on response to change and discriminative capacity of fatigue in IBD patients have been reported (Table 1) .
The Multidimensional Fatigue Inventory (MFI) is widely used and shows very good internal consistency. Like many other scales, it has been developed in other chronic specific diseases and has been applied for detection of IBD fatigue [31] . It consists of a 20-item questionnaire on a 7-point Likert scale measuring five dimensions, including general fatigue, physical fatigue, mental fatigue, motivation, and activity [31] . Due to the length of the questionnaire however, it may be difficult to implement this as a quantification tool in larger studies. The Multidimensional Assessment of Fatigue (MAF) is a 16-item scale that measures fatigue according to four dimensions: degree and severity, distress that it causes, timing of fatigue (over the past week, when it occurred, and any changes), and its impact on daily activities [32] . The Checklist Individual Strength (CIS) is a validated score system, with good reliability and sensitivity, and discriminates fatigue from depression [33] . It is a 20-item instrument on a 7-point Likert scale measuring the severity of fatigue, motivation, physical activity level, and concentration over the past 14 days. A shortened 4-item, 7-point Likert scale version of this questionnaire, the Short Fatigue Questionnaire (SFQ), is also available. The SFQ has shown good internal consistency and is able to discriminate fatigue in the general population, but has not been validated in IBD [34] . A more custom-made Inflammatory Bowel Disease Fatigue (IBD-F) scale has recently been developed [35] . It is the only one scale that has been developed specifically for IBD patients. It takes an average 10 min to complete and has shown good test-retest reliability and correlation with the MFI and MAF scale [23] . It consists of three sections: identifying the level and duration of fatigue, the impact of fatigue on daily activities, and identifying causes and other factors related to fatigue. The 13-point Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) was also evaluated in IBD [3] . Finally, a singleitem Visual Analog Scale (VAS) may represent a good highthroughput alternative. The VAS was compared with three longer questionnaires (the MAF, the Short Form 36, and the Brief Fatigue Inventory) to assess fatigue in patients with rheumatoid arthritis [36] . All questionnaires were highly correlated, whereas the three longer questionnaires had slightly greater reliability in cross-sectional analyses; the VAS was at least as good when sensitivity to change was considered [36] .
Next to scoring fatigue as a trait, its effect on the healthrelated quality of life is well established. Therefore, a measure for the quality of life is often included. The Inflammatory Bowel Disease Questionnaire (IBDQ) was developed together with IBD patients and was validated [37, 38] . The EuroQol-5D (EQ-5D) system is a descriptive 5-item quality-of-life measure that includes mobility, self-care, usual activities, pain/discomfort, and anxiety/depression [39] .
Given the confounding effect of depression and anxiety as potential causes of fatigue, assessment of these conditions is warranted. The Hospital Anxiety and Depression Scale (HADS) is a validated 14-item questionnaire capturing both anxiety and depression [40] . In addition, the Depression Anxiety Stress Scale (DASS) [41] also differentiates between stress. Finally, possible age, sex, ethnic, educational, and socioeconomic factors are not typically included in these questionnaires, and therefore should be considered as co-variables.
In summary, a fully validated scale to measure fatigue in IBD for use in clinical trials and daily clinical practice is still lacking. Efforts should be made to develop a scale that not only captures the multidimensional aspects of fatigue reported by the patients (in other words, has an optimal content validity) but also shows a high internal consistency responsiveness to change.
Factors Associated with Fatigue in IBD (Fig. 1) Once IBD-related fatigue is diagnosed, it is important to know that in many cases, both physical and psychological factors are involved and that these may change and/or evolve over time. In the next section, we provide an overview of the factors that may influence the onset or severity of fatigue in IBD.
Inflammation
Fatigue is definitely more prevalent in patients with clinically active disease as compared to patients in clinical disease remission (60-80% versus 20-40%, respectively) [21, 29, [42] [43] [44] . Associations between fatigue and inflammatory markers such as the erythrocyte sedimentation rate and Creactive protein (CRP) have been found [45] . It has been hypothesized that activation of the immune system induces the production of pro-inflammatory cytokines (IL-1, IL-6, and TNF-a) which determine a sickness behavior via several immune-to-brain communication pathways and/or directly and negatively affect muscle performance. Impaired muscle performance causes an impaired physical fitness leading to further deteriorating fatigue [46] . However, it remains unclear whether fatigue during active disease is a direct consequence of systemic inflammation or whether it is just associated with the total symptomatic burden.
In a Norwegian observational study on 82 newly diagnosed UC patients, there was a clear relationship between fatigue and symptoms, but not with objective disease markers such as fecal calprotectin or endoscopic scores [25] . After 3 months, fatigue improved in line with the digestive symptoms [25] .
Nevertheless, it is known that the release of proinflammatory cytokines may act on the brain to induce sickness behavior-like symptoms such as fatigue and anxiety which may eventually evolve in real mood disorders such as depression [47] . The existence and importance of a bidirectional gut-brain axis has recently appeared as a subject of intense research and animal models are particularly useful in this regard [48] . A Dutch research group compared a large variety of immune parameters between patients with IBD with fatigue (N = 55) and without fatigue (N = 29) [27] . Importantly, all patients in their cohort were in clinical remission (Crohn's Disease Index (CDAI) < 150 or an ulcerative colitis index < 10) and had a serum CRP value below 10 mg/L and a fecal calprotectin level below 200 μg/g. Median serum IL-12 and IL-10 were significantly higher and I (p = 0.005) and lower for IL-6 significantly lower in the fatigued group as compared to non-fatigued patients (P < 0.001, P = 0.005, and P = 0.002, respectively). Results of flow cytometry and whole blood stimulation tests supported a chronically active and Th1-skewed immune system in patients with fatigue [27] .
The fact that fatigue prevalence is comparable among different immune-mediated inflammatory diseases such as IBD, psoriasis, and spondyloarthritis (with a rate range from 40 up to 80%) further supports a causal relationship between chronic inflammation and fatigue although the exact pathogenic mechanism remains to be elucidated [49] .
Anemia and Iron Deficiency
Anemia is the most common extraintestinal manifestation of inflammatory bowel disease (IBD) and, in most cases, results from an absolute or functional iron deficiency. Fatigue can be a symptom of anemia but a causal relationship between anemia and IBD-related fatigue has not been uniformly reported. Some studies found an association between low hemoglobin levels and IBD-related fatigue [42, 45, 50] whereas others did not [7, 44] . Goldenberg et al. found no significant association between iron deficiency with or without anemia and problematic fatigue in 280 IBD patients within the population-based Manitoba IBD Cohort Study [51] . Still, it is important to actively screen for iron deficiency and anemia in patients with IBD, as intravenous iron supplementation seems to be able to increase the patient's QoL in the setting of both anemic and non-anemic iron deficiency [52, 53] .
Nutritional Deficiencies
Apart from iron, many other nutrient deficiencies have been associated with fatigue in specific disease populations, including zinc [54] , folate [55] , vitamin B12 [56] , and vitamin D [57] ). Although the relationship between these deficiencies and fatigue has not specifically been found in the IBD population, it is recommended to screen for them and to start supplements if necessary.
Hormonal Disturbances
IBD patients with long-lasting courses of corticosteroids should be tapered very slowly to avoid a steroid-withdrawal syndrome due to adrenocortical insufficiency. If not, these patients can present with severe fatigue and muscle weakness. Outside this context, fatigue does not seem to be related to low cortisol levels in quiescent IBD [58] .
Although uncommon, IBD (and especially CD) can be associated with thyroid diseases such as Hashimoto thyroiditis which may present with fatigue [59] . It is therefore recommended to include the thyroid function tests in the workup of fatigue in IBD.
Drug-Related Factors
The relationship between IBD drugs and fatigue is complex. In IBD patients with fatigue and active disease, effective conventional management may lead to improvement or complete alleviation of fatigue [25, 60, 61] . On the other side, some evidence that the drugs themselves can induce or worsen fatigue can be found in literature. Many papers report a positive association between the use of different drugs (corticosteroids, thiopurines, TNF antagonists) and fatigue [21, 43, 58, 62] . However, it is unclear whether increased fatigue in this case is related to the drug itself or just to a more severe disease necessitating these drugs. Studies in which withdrawal of the drug improves fatigue are more convincing. In a recently published case series of 5 patients with an onset of fatigue temporally linked to the introduction of azathioprine or 6-mercaptopurine, complete resolution of fatigue was seen after withdrawal of the drug [63] . A same observation has been made for TNF antagonists [64] . With regard to the latter, Brandse et al. found a trend towards higher fatigue scores in IBD patients in clinical and biochemical remission with infliximab or adalimumab trough levels above the median [24] . In a recently published systematic review and meta-analysis, a linear duration-response relationship was found between duration of anti-TNF therapy and the risk of fatigue.
Sleep Quality and Psychological Factors
Poor sleep quality is consistently associated with increased fatigue scores [5, 29, 44, 65] . The same holds true for stress, anxiety, and a depressive mood, although the direction of causation remains unclear [5, 29, 44, 65] . The use of psychotropic medication obviously has a negative impact on the fatigue burden in IBD [5] . An all-or-nothing and avoidance behavior has also been linked to an increased impact of fatigue on the QoL [26] . Vice versa, patients with a self-directed personality, adaptive behavior, and/or a higher sense of coherence experience a lower fatigue burden [66, 67] .
Studying Fatigue in Animal Models
To induce progress in our understanding of fatigue as a symptom of IBD, well-validated animal models are required. These models will permit to perform controlled studies targeted to pinpoint underlying molecular mechanisms and to design novel therapeutic approaches. One of the most important benefits of an animal model is that fatigue as a trait can be objectified, since psychologic disturbances will not affect the outcome.
Fatigue in humans typically is assessed by self-report, whereas in animals, the subjective state of the animal must be inferred from their behavior. The use of appropriate animal models for fatigue, mainly in rodents, has recently begun to advance our understanding of the underlying neurobiology (reviewed in [68] ), and automated monitoring systems to measure animal behavior have greatly advanced this field of research. Some important experimental aspects need to be considered, in particular to reduce any environmental stress level in the animal that will interfere with the measurements. The tests should be performed in a quiescent environment, without the presence of other animal species. Ideally, the tests are conducted by one investigator, who is aware of not exposing the animals to bright colors and strong odors. One might even account for the fact that olfactory exposure to male stimuli is stressful for mice [69] . In addition, the tests should be performed simultaneously with mice housed in one cage in which hierarchy has been established, avoiding any disturbance of hierarchy by removing mice from the cage one by one.
In general, it is recommended to use a combination of behavioral tests to investigate the different aspects of fatigue [70] . Spontaneous physical activity is a good surrogate indicator of fatigue, as it captures reduced physical activity observed in humans. Because rodents are relatively inactive during the light phase of the diurnal cycle, fatigue is ideally monitored during the dark phase. Spontaneous activity can be measured by intraperitoneal implant of a receiver, detecting a signal each time the animal crosses a specific location in the cage. Wheel-running activity is another important indicator of locomotor activity, in which revolutions of the wheel are typically recorded every 10 min, and is averaged over predefined periods. Also, the diurnal pattern of spontaneous activity is a reliable measure, since circadian rhythm is frequently affected by fatigue in humans. Wheel running was more sensitive (i.e., larger window) than activity on the cage floor to capture chemotherapy-induced fatigue [70] and was validated because the results of this test was improved by treatment with Modafinil, reducing fatigue in this group of patients [71] .
Forced locomotor activity is another way to determine physical sensations; however, one must be aware that this will be influenced by the stressful manipulation of the animal. Forced treadmill running, or the Rotarod performance test, is frequently used and captures fatigue resistance, motor coordination, and motor learning. In the test, the animal is placed on a horizontally oriented, rotating cylinder suspended above a cage floor. Rodents will naturally try to stay on the rotating cylinder. After a test phase, the length of time that the animal remains on the rod is measured. The forced swim test (also called the Porsolt swim test) is based on behavioral despair because the animals do not have the ability to escape the stressful environment [72] . The animal is placed in a 2-L recipient of which 2/3 is filled with water. Rodents are good swimmers and the period for which a given animal is able to stay above water is to be measured. In mice, the test is onedimensional, whereas in rats, swimming, climbing, and immobility are observed, which can discriminate between serotonergic (swimming behavior) and norepinephrine mechanisms (climbing behavior) [73] .
Fatigue in humans can be accompanied by either excessive sleep patterns or difficulties of sleep. The sleeping pattern in rodents can be measured via electroencephalographic and electromyographic data, in which animals are hitched to an electrical swivel via a lightweight cable. Specific vigilance states (slow-wave sleep, rapid-eye-movement sleep, or awakening) can be monitored.
Decreased concentration and memory loss in humans can be captured by cognitive tests in animals. The Y-labyrinth test is based on the innate preference of rodents to explore a place they have not discovered yet and detects spatial memory. For 6 min, the animal is placed in a Y-shaped maze and the amount of time and in which order the animal enters one of the arms is monitored. The novel object test is another test to evaluate short-and long-term memory. The procedure consists of two phases: the training phase and test phase. During the training phase, the animal is placed in an arena and is allowed to explore two identical objects, which are placed in opposite positions at identical distance from the nearest corner. Thereafter, the animal is placed for 15 min back in its cage. Subsequently, the animal is allowed to explore the same arena in which one of the objects was replaced by another object. When the animal pays more attention to the new object, this is a sign of recognition of the old object. From that moment on, the 5-min lasting test phase starts, which is based on the spontaneous behavior of the animal to explore the new object. To test long-term memory, the animal is placed in the box for the test phase after 24 h.
Finally, anxiety, which is an important confounding factor of fatigue in humans, can be detected by the open field test. The velocity of movements, distance moved, and time spent in the center and periphery of a box is monitored. Spending more time in the periphery is regarded as a sign of anxiety. The light/dark test is another measure for anxiety, based on the innate aversion of rodents towards highly illuminated space. The animal is placed in a maze consisting of a dark space and an illuminated space, connected by a passageway. The animal is placed in the illuminated compartment and during 6 min, the amount of time spent in each compartment is monitored [74] .
The validation of animal models for fatigue in IBD (i.e., inducible and treatable by agents tested in humans) has not been addressed, mainly because no therapeutic agents have been identified. For experimental enteritis, a large number of models are available [75] . Typically, behavioral tests as a proxy for fatigue will be performed in mice in which experimental enteritis was induced. It will be of utter importance to correlate these measures with disease activity, including anemia, food and water intake, and cytokine concentrations in circulation, since growing evidence suggests that increases in pro-inflammatory cytokines may promote fatigue by inducing sickness behavior, i.e., listlessness, lethargy, and decreased food and water intake [46] . Practical Approach to the IBD Patient with Fatigue ( Fig. 2) When assessing fatigue as a symptom in IBD, it is important to discriminate it from Bnormal^fatigue experienced by a healthy individual which is a state of fatigue experienced after exercise that declines after a period of time. Fatigue due to clearly identifiable external factors such as a new highdemanding job or a crybaby should also be excluded. Fatigue arising in the context of a major depression is a separate entity that should be identified. This can be challenging but in general, patients with IBD-related fatigue are keen to perform activities but feel limited to do them, while patients with depression-related fatigue are apathetic and feel empty. Likewise, fatigue can also be part of a generalized anxiety disorder in which patients experience a non-specific persistent fear and worry related to everyday matters resulting in restlessness and sleep disturbance. Whenever a mood disorder is suspected, we recommend a referral to the psychiatrist for further assessment. Alcohol and/or drug abuse are related with emotional distress, poor sleep quality, and anxiety, and should always be assessed in the workup of IBD-related fatigue [14] .
When fatigue presents in a patient with active disease, IBDspecific treatment should be started and a re-evaluation should be performed when remission is reached since in many cases, fatigue improves along with the other symptoms. Intravenous iron supplementation is recommended when iron-deficiency anemia is present. If fatigue persists or starts despite a tight disease control, it is important to not ignore the problem and to acknowledge that it may have a considerable impact on the QoL of the patient. We routinely perform a laboratory screening including hemoglobin, serum creatinine, liver function tests, iron parameters, zinc, folate, vitamin B12, vitamin D, and thyroid function tests and a screening for CMV, EBV, and toxoplasmosis as potential causes of prolonged fatigue. In most cases, this is frustrating and no direct cause can be identified. At present, no drugs are available with a proven indication for IBD-related fatigue during disease remission. A common pitfall in this scenario is to grant long-lasting absence from work, which may lead to further physical inactivity and social isolation of the patient, both of which can have a negative impact on the fatigue burden [76, 77] . According to some supportive evidence, physical activity may be beneficial for individuals with IBD. Exercise improves immune function and mood, reduces fatigue, and promotes gains in muscle and bone strength [78, 79] . However, people with IBD experience considerable barriers to exercise, related to intermittent nature of the disease and its symptoms such as pain, fatigue, and fear of fecal incontinence [80] . Psychotherapy should be offered to the patient as this has been shown effective in a recent systematic review [81] . Solution-focused therapy consisting of 7 sessions focusing on coping styles for fatigue over a 6-month timeframe had a significant beneficial effect on the severity of fatigue and QoL in a randomized controlled trial (RCT) including 98 patients with clinically and biochemically quiescent IBD, but the effect rapidly faded out upon cessation of this therapy [82] . Training in self-directed stress management also led to a reduction in tiredness in another RCT in patients with quiescent CD [83] .
Conclusion
Fatigue is a highly prevalent and burdensome symptom in patients with IBD, with an important impact on the QoL and the (indirect) health expenditures. Patient-reported outcomes are a major therapeutic goal in IBD and should be included in the assessment of disease severity. The Food and Drug Administration (FDA) claims the use of patient-reported outcome measures in the endpoints of future clinical trials. Despite the availability of a large variety of scales to measure fatigue, none of them has been developed according to the FDA guidelines and none of them have undergone a complete validation process (including reliability and responsiveness studies).
Knowledge on the mechanisms contributing to fatigue in IBD, especially in quiescent disease, is largely lacking. Rodent models can be used to identify the key molecular pathways leading to fatigue in chronic intestinal inflammation, which will hopefully lead to the availability of more targeted therapy to tackle this unmet need in IBD patients.
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